HIGH RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。(来自国家癌症研究所PDQ数据库的临床试验摘要)化疗中使用的药物，如地塞米松、泼尼松、甲氨蝶呤和亚叶酸钙，以不同的方式阻止癌细胞分裂，从而停止生长或死亡。给予一种以上的药物可能会杀死更多的癌细胞。目前尚不清楚哪种联合化疗方案治疗急性淋巴细胞白血病更有效。这项随机的第三阶段试验正在研究地塞米松，以了解它在诱导治疗中与泼尼松相比效果如何。这项试验还在研究甲氨蝶呤和亚叶酸钙，以了解在维持治疗新诊断的急性淋巴细胞白血病患者中，它们与单独使用甲氨蝶呤的效果如何。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia. This randomized Phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia.